Particle.news
Download on the App Store

Bankruptcy Court Clears CVS Sale of Omnicare to GenieRx for $250 Million

The ruling lets CVS shed a struggling unit at a fraction of its 2015 purchase price.

Overview

  • The Texas bankruptcy court's approval on Wednesday cleared the $250 million sale of Omnicare to GenieRx, with closing expected later in 2026 pending regulatory review.
  • GenieRx is a buyer formed by Milrose Capital and Integro Healthcare Services, which says it plans to strengthen service for long‑term care partners.
  • Omnicare is the largest U.S. nursing‑home pharmacy and fills tens of millions of prescriptions for residents in skilled‑nursing and assisted‑living facilities, so steady service remains a central concern for caregivers and families.
  • The sale follows a 2025 federal judgment of about $949 million after a court found more than 3.3 million false claims tied to invalid prescriptions, prompting a Chapter 11 filing in September 2025.
  • CVS bought Omnicare for nearly $13 billion in 2015, making this a steep write‑down as CVS narrows its strategy after moves like pulling Aetna from ACA exchanges and slowing clinic expansion.